Donanemab for Alzheimer's Disease
This trial is studying how safe and effective donanemab is in treating early Alzheimer's disease.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 2 trial • 272 Patients • NCT03367403
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are we able to sign up for this trial right now?
"This particular clinical trial is not currently recruiting patients. However, it was initially posted on 6/19/20 and edited as recently as 8/3/22. If you are interested in other studies, 562 clinical trials for alzheimer disease and 4 studies for Donanemab are actively searching for participants."
Does this clinical trial have an age limit? If so, what is the maximum age of participants?
"The age limit for candidates eligible for this trial are between 60 to 85 years old."
How many different medical facilities are running this clinical trial?
"There are 100 recruiting patients for this study such as Sensible Healthcare, LLC in Ocoee, Senior Adults Specialty Research in Austin, and Arch Clinical Trials, LLC in Saint Louis."
What is the current regulatory status of Donanemab?
"Donanemab has received a 3 for safety from our team at Power. This is because it is a Phase 3 trial, and there is thus some data supporting efficacy as well as multiple rounds of data affirming safety."
How many patients are currently enrolled in this trial?
"Unfortunately, this study is not enrolling patients at the moment. The listing was created on June 19th 2020 and updated as recently as August 3rd 2022. There are 562 other trials for patients with Alzheimer's disease that are still recruiting participants along with 4 clinical trials for Donanemab."
Can you provide some context for this Donanemab study by detailing other research that has been conducted in the past?
"Donanemab was first studied in 2020 for its efficacy in treating Parkinson's Disease and Movement Disorders. Since then, there have been 18290 completed clinical trials worldwide. As of now, there are 4 live studies-- a significant number of which are based out of Ocoee, Texas."
To whom does this study's eligibility requirements apply?
"The target population for this study are those aged 60 to 85 who have Alzheimer's disease. Out of these patients, 1800 will be enrolled. Furthermore, it is a requirement that they have a Mini-Mental State Examination (MMSE) score between 20 and 28 at the start of the trial as well as having had gradual changes in their memory function over a period of at least six months."
Has a clinical trial like this been conducted before?
"There are 4 ongoing clinical trials for Donanemab in 334 cities across 9 countries. The very first study was completed in 2020 and it received Phase 3 drug approval. Since then, 18290 more trials have been completed."